Summary
The data on 914 patients enrolled in four randomised trials in advanced ovarian cancer, consecutively conducted by the same cooperative group between 1978 and 1986, were analysed with the aims of: (1) determining the impact of selected prognostic variables on survival; (2) finding, from the interaction of favourable prognostic factors and treatment, an approximate estimate of the magnititude of the survival advantage associated with the use of platinum-based combination chemotherapy. The overall 3-year survival in this series of patients is twice that reported historically (22%; 95% CL 18.7--25.4). The proportional hazard regression model was used to perform the analysis on survival. Residual tumour size, age, FIGO stage and cell type were all independent determinants of survival. Differences in survival from the various prognostic groups were impressive with 5-year survival rates ranging from 7 to 62%. However, these differences were not qualitative (i.e. the kinetics of survival were similar for the best and the worst groups) suggesting that current prognostic factors are of little use for selecting 'biologically' different sub-populations. Platinum-based regimens were associated to an overall prolonged median survival, but this benefit was not observable in the subgroup with most favourable prognosis (<2 cm residual tumour size). The implications of these observations for clinical research and ovarian cancer patients care are discussed.
Cancer of the ovary ranks sixth as a fatal form of cancer in women and is the second cause of death for gynaecological malignancies in Italy. Approximately 4,000 women die of it every year in Italy (Cislaghi et al., 1986) .
In the mid 1970s surgery and radiotherapy played major roles in the management of this disease while chemotherapy, although extensively explored, was still considered experimental. Survival rates at 5 years were below 10% in the advanced stages, representing more than 70% of patients at diagnosis.
Among the clinical research goals set forth at that time was the determination of prognostic factors. As for other tumours, prognostic determinants were sought to understand the natural history of the disease, to adjust for randomisation imbalances in the interpretation of clinical trials results and to provide clinicians with guidelines for decisions on treatment strategies and for dealing with the patients and their relatives. Earlier studies were generally based on univariate analyses (Richardson et al., 1985) , and their conclusions are marred by all the pitfalls associated with a statistical method not accounting for interactions between different variables. Griffiths (1975) was the first to use multiple regression and multivariate analysis of possible prognostic factors, but his database was small (102 cases) and comprised also stage II patients. Recently several studies (Swenerton et al., 1985; Redman et al., 1986; Gruppo Interregionale Cooperativo Oncologico Ginecologia, 1987; Neijt et al., 1984 Neijt et al., , 1987 GGCOSA, 1986) Bolis et al., 1980; Sessa et al., 1985; Mangioni et al., 1989) . Table I gives a synopsis of treatments in the four trials. Figure la and b shows the overall survival curve and the curves for the entire population stratified according to the six prognostic classes. Figure 2a gives the curves by residual tumour size alone and Figure 2b the curves for the <2 cm population further broken down (microscopic, <1 cm, 1-2 cm). The population with microscopic disease was equally distributed between the two first sub-groups of risk categories ( < 2 cm, good risk and <2 cm, poor risk). Figure  4a ( < 2 cm), b (2-S cm) and c (> 5 cm). In the subgroup of 246 patients with residual tumour size below 2 cm the survival curves for the four trials are completely superimposed and the worse survival experience observed for the whole population in trial no. 1 (C vs AC) is no longer detectable Figure 3 Survival by trial: * trial 1-AC/C, A trial 2 HAC/ PAC, U trial 3 PAC/CP/P, 0 trial 4 carboplatin/P 100. In parenthesis is the O/E after stratification by residual tumour size (< 2 cm, 2-5, > 5 cm).
( Figure 4a ). However, the pattern of a marked difference between trial 1 and all the others, and with the caveat of the shorter follow-up, the superiority of trial 4, reappears when plotting the survival curves for the > 2 cm sub-groups ( Figure 4b , 2-5 cm; Figure 4c , >5 cm).
Discussion
The .s. with markedly different survival experience (Figure lb) . PS was another strong independent factor affecting survival. The addition of this variable in the Cox model yielded a 1.5 relative risk of dying for patients with a PS score below 90, while nullifying the influence of stage and age. This is not surprising since PS could be a 'comprehensive' marker of the same relationship between the patient's status and the extent of disease expressed by the combination of stage and age in the first model, despite the different nuances.
While all published papers on multivariate analysis agree on the importance of residual tumour as a prognostic determinant, the prognostic importance of all other variables varied from one study to another (Griffiths, 1975; Swenerton et al., 1985; Redman et al., 1986; Gruppo Interregionale Cooperativo Oncologico Ginecologia, 1987; Neijt et al., 1984 Neijt et al., , 1987 . This may be accounted for by both the small populations studied (in all cases fewer than 200 patients were analysed) and the different 'cocktails' of factors considered (several included weight loss, other excluded age and/or stage, etc). The strength of this study is the large sample on which results are based. However, the relevance of prognostic factors other then residual tumour size should be further tested to avoid biases inherent to retrospective and subgroup analysis. The results presented in Table IV and Figure lb need to be prospectively validated on an independent data set.
Approximate magnitude of the survival advantage associated with platinum-based combination chemotherapy in ovarian cancer The overall 5-year survival rate in advanced epithelial cancer in this series of 852 patients treated between 1978 and 1987 is twice that reported historically (Richardson et al., 1985) for 5,254 cases collected from 1973 to 1974 (22.1, 95% CL 18.7-25.4 vs 10.4% ). In addition the 1, 2 and 3 year survival figures are practically the same as in the most recent trials utilising aggressive polychemotherapies like the CHAP-5 regimen (Neijt et al., 1984 (Neijt et al., , 1987 ).
Since we pooled data from four consecutive trials, in the multivariate analysis we considered type of treatment only as a correcting factor for determining the influence of the various prognostic variables on survival. However, survival was also influenced by treatment or at least by type of strategy, as can be seen from Figure 3 and Table VI . This observation must be tempered in consideration of the historical nature of our analysis which can be biased by changes in the characteristics of the treated groups and in the types of ancillary treatment and/or diagnostic work-up (Table II suggests a worsening of the patients over time, in spite of a higher incidence of more aggressive surgery). That not withstanding, patients treated with the earlier strategic approach, single agent cyclophosphamide or a combination of cyclophosphamide and adriamycin did worse than all the others. Patients exposed to cisplatin -either alone at high-doses (100 mg m2) or in combination (CP, CAP) at low-doses (50 mg m2) -did better, but the HAC treated patients did no worse than the previous category. However, if platinumbased chemotherapies -either single agent or combinationsseem to have prolonged the median survival time in advanced ovarian cancer patients, the fraction of long-term survivors has not increased markedly, especially in the sub-group most susceptible of being cured (i.e. patients with less than 2 cm residual tumour, Figure 3a) . In fact, results from randomised trials, our own (Gruppo Interregionale Cooperativo Oncologico Ginecologia, 1987) and more recent ones (Neijt et al., 1987; Omura et al., 1983; Tomirotti et al., 1988) , suggest that if a difference exist between less aggressive regimens (cisplatin, cisplatin + cytoxan) and CAP is of an order of magnitude much lower than that hoped for in the early 1980s (i.e. less than 20%).
Implications for clinical research and care in ovarian cancer Prognostic factors are sought not only to help understand the natural history of a disease but also for more 'decisional' purposes in both clinical practice and research.
In clinical practice, the knowledge that advanced ovarian cancer patients can be assigned to groups with distinct prognostic characteristics may serve doctors as a guideline for a more accurate estimate of the trade-offs between toxicity and survival offered by chemotherapy.
In clinical research, prognostic factors are often used for adjusting for randomisation imbalances in the analysis/interpretation of clinical trial results. This work suggests there is great heterogeneity -in terms of survival probabilitieswithin an apparently homogeneous population, historically labelled as 'advanced disease'. The difference in survival between the best-prognosis group and all the others is impressive. It follows that the results of any trial could quite dramatically change -and independently from the real impact of whatever experimental treatment was testeddepending on the size of this fraction of patients. Since generally not more than 20% of the patient population for a given tumour type, including ovarian, seen at any given institution (Wittes & Friesman, 1988) , enters controlled clinical trials, this kind of selection bias could conceivably play a role in up-grading (or down-grading) the final results of the trial itself. This might partially explain the different results obtained by different centres/investigators utilising similar regimens in advanced ovarian cancer (Tomirotti et al., 1988; Neijt et al., 1987; Decker et al., 1982; Bell et al., 1982; Conte et al., 1986; Williams et al., 1985; Young et al., 1978; Bertelsen et al., 1987; Wilbur et al., 1987; Carmo-Pereira et al., 1983; Omura et al., 1986) . It also strikes a point against historical comparisons in which the lack of randomisation is even more likely to unbalance the prognostic subgroups and consequently introduce powerful biases in the conclusions.
To facilitate international communication of data, common criteria for defining and reporting risk groups in this disease should perhaps be developed and agreed upon, as has been done for other diseases (Mastrangelo et al., 1986) .
The second implication for clinical research stems from the recognition that the differences in survival among the various prognostic groups, although impressive, are quantitative, not qualitative. In other world the 'kinetics' of survival of the best and worst risk groups are similar. Thus the current prognostic factors are useless for selecting a 'biologically' different sub-population, as was done, for example, within the acute leukaemias for the B immunophenotype. The current prognostic factors in ovarian cancer probably represent a too remote epiphenomenon(a) of the underlying abnormality(ies) to be of use for this purpose.
Finally, no striking differences were observed in the longterm results with eight different mono or polychemotherapy regimens. The results of other randomised clinical trials in the past decade point in the same direction (Gruppo Interregionale Cooperativo Oncologico Ginecologia, 1987; GGCOSA, 1986; Bell et al., 1982; Williams et al., 1985; Dembo, 1986; Burslem & Wilkinson, 1986) . They suggest a superiority in terms of response and progression-free disease of combination chemotherapy over single-agent alkylators or cisplatin, but are ambiguous in terms of survival and cost/ benefit ratios possibly because much larger sample sizes are needed to detect small survival differences (i.e. 10% or less).
The implications are two-fold: first that clinical research in this disease has reached a plateau phase, and secondly that efforts should be directed beyond the repetitive area of comparing 'new' combinations of old drugs. Perhaps while awaiting new drugs or truly innovative new ideas, clinical research in this area should tackle the fact that although cisplatinbased chemotherapy seems to play an important role, we are far from having established any universally acceptable standard.
